Evaluation of in vitro release methods for liposomal drug products

The summary for the Evaluation of in vitro release methods for liposomal drug products grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food Drug Administration, which is the U.S. government agency offering this grant.

Evaluation of in vitro release methods for liposomal drug products: The development of generic liposomal drug products is challenged by a lack of compendial or bio-relevant in vitro release methods. The traditional in vitro release method relies on dialyzing the liposomal formulation against a large volume of buffer. This method suffers from poor in vivo predictive power due to its inability to mimic the complex in vivo release conditions such as the large membrane pool present in systemic circulation or drug release conditions at the tumor sites or in the macrophages. Modifications to the traditional method include dialyzing against serum, serum protein solution, or surfactant solution and performing multiple stage dialyses. In addition, advances in separation techniques, such as filtration, centrifugation, and solid phase extraction, makes possible novel in vitro release assays in the presence of excess acceptor multilamellar or unilamellar vesicles. The robustness and predictive power of these methods have not been systemically evaluated or compared for specific type of liposomal drug products. The optimization and establishment of a standard in vitro release assay will advance the regulatory review of generic liposomal product applications.Objectives: The purpose of this study is to evaluate different in vitro release methods for liposomal drug products and analyze their robustness, capability of detecting formulation differences, and predictive power for in vivo performance. This study is intended to advance the regulatory review process of generic liposomal drug products, which in turn will help provide the US public with access to high quality generic liposomal drug products.Detailed description: Using amphotericin B, daunorubicin citrate, or vincristine sulfate liposomal injection as a model drug product, the project will involve the following:a. Review available in vitro release methods for the selected model liposomal drug product(s).b. Prepare a series of liposome formulations with similar formulation composition to the marketed model product but with different process conditions. Characterize physicochemical properties including mean particle size and distribution, surface charge, pH, shape, lamellarity and others.c. Conduct dissolution studies of prepared liposome formulations (including the marketed model product) with various in vitro release methods. Both conventional methods and innovative in vitro release study design can be explored. d. Vary in vitro release conditions and identify critical factors that affect the performance of each type of in vitro release method evaluated.e. Identify in vitro release methods which can distinguish liposome formulations with different in vitro characteristics. Use the in vitro release data together with animal data or human data to establish an in silico platform and explore in vitro in vivo correlation of selected liposomal drug product(s).